Allarity Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Thomas H. Jensen (CEO) and Jeffrey Ervin (CFO) certified the June 30, 2026 Form 10-Q on August 14, 2026, attesting that the report contains no untrue material statements, financial information fairly presents the company's condition and operations, and disclosure controls and internal controls over financial reporting are effective. No deficiencies, weaknesses, or fraud were disclosed.
Why this rating
Boilerplate SOX 302/906 certification with no material findings disclosed; standard quarterly filing requirement, immaterial relative to $14.7M market cap
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.